NanaBis is packaged as a mouth spray and will be clinically tested in advanced stage cancer patients with intractable pain.
The drug is expected to meet a global need for better pain management, with research having shown cancer pain was an increasingly widespread condition.
Recent statistics regarding cancer pain indicate it is prevalent in 64% of patients with metastatic or advanced-stage disease and that for one in two patients with cancer, it is undertreated.
With the recent U.S. crackdown on opioid abuse, there is a significant need for better, efficacious treatment.
NanaBidial comprises cannabidiol derived from marijuana and is indicated for chemotherapy induced nausea and vomiting, with a secondary endpoint in patients suffering seizures.
The drug is intended to be made available to general practitioners so it would give many